Rodrigo Hepp

Radiation oncologist, Head of department @ Evangelische Kliniken Gelsenkirchen | Dedicated to Brachytherapy | SGRT

[Angel Montero Luis @Monthy_A]

Hypofractionated whole-breast radiotherapy with simultaneous integrated boost led to a clinically relevant reduction in worst grade radiation dermatitis: Results from the randomized controlled HYPOSIB-trial (ARO 2013-05), by @DavidKrugMD #radonc #bcsm
https://t.co/YaPTux4mhY

[Tyler Seibert MD PhD @TylerSbrt]

🚨Want to learn more about how to do focal RT boost for #ProstateCancer?

3 new guides we have been working on all happened to come out within ~1 week of each other. Links in 🧵👇🏼

#radonc

[Icro Meattini @Icro_Meattini]

Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective @JCO_ASCO

@OncoAlert #OncoAlert

https://t.co/Q2bopcUuHY

[Dr. Nina Niu Sanford @NiuSanford]

One of most interesting rectal ca studies at #ASCO26

P3 RCT in pMMR LARC: Node-sparing short-course RT + CAPOX + tislelizumab doubled pCR v conventional SCRT + CAPOX (61 v 29%)

Hypothesis = sparing elective node RT preserves antitumor immunity & improves PD1 response @OncoAlert

[Jay Detsky @jaydetsky]

I was curious what AI (Claude, to be specific) would make of the editorial from my urology colleagues about cumulative incidences of RT toxicity vs a similar analysis post radical prostatectomy.... /1

[NonsparseOncologist @5_utr]

Bertolo & Develtere want cumulative incidence for RT counseling. Fine. ProtecT at 12 years: urinary leakage requiring pads 18-24% surgery vs 3-8% radiotherapy (Donovan, NEJM Evidence 2023). Applying their own framework to surgery produces numbers they’d never publish. Funny that.

[Jakob Wasserthal @JakobWasserthal]

Exciting Update: TotalSegmentator supports segmentation of liver lesions on both CT and MR images. Free and easy to use. Great team effort by the University Hospital Basel Radiology team.

paper: https://t.co/6d6dcO7cfN
code: https://t.co/BblnCvoKAw

[Priyamvada Maitre @docpriyamvada]

Stereotactic Radiotherapy has transformed our field, and everyone should benefit!

🗺️From Constraints to Confidence: A Roadmap of 'Simple' SBRT 🗺️

Our thoughts in the SBRT special issue of @IJROBP 🥰
Free link⤵️
https://t.co/T2Mfc3pygm

[Daniel E Spratt @DrSpratticus]

#GU26 Up next: 15 yr OS from the ASCENDE-RT RCT of external beam boost versus brachytherapy boost in localized prostate cancer
- Prospective f/u ended at 10 years, but death certificates and other data sources were looked beyond 10 years (so high risk of attribution bias, no further DM data presented, etc).

-Median age of patients at 15yrs are 82yo; 54% of patietns have died (younger and healthier cohort than most RT trials)

-No difference in OS (p=0.8) on UVA or MVA.
-PCSM better in brachy arm, which means that OCM was worse in brachy arm (numerically). Could all simply be attribution bias.

@HimanshuNagarMD @seanmmcbride @AmarUKishan @ASCO

[Elena Castro @Ecastromarcos]

📢The updated ESMO guidelines on localised and advanced prostate cancer have been published!

Localised:
https://t.co/iuvNeYwh3f

Advanced: https://t.co/hErf4ICPHX

@myESMO @APCCC_Lugano @Annals_Oncology

[The Lancet Oncology @TheLancetOncol]

🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

https://t.co/x5xngvO2qP

[Chad Tang, MD @ChadTangMD]

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: https://t.co/du9hQOzHv7.

The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

[Clive Peedell @cpeedell]

@DrSpratticus @MRoupret @EurUrolOncol @ESTRO_RT @Uroweb Too kind, Daniel.
He needs to apologize, resign and retract the paper. There are already urologists quoting it and no doubt it will come up in patient consultations soon.
Look at this textbox summary in paper. Shocking. Even quotes wrong number of patients (factor of 4 out!)

[Michael Serzan, MD @MikeSerzanMD]

👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25

🐺Dr @ChadTangMD presenting Abs15 "World-wide oligometastatic prostate cancer (omPC)meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration"

5⃣ RCTs omPC: MDT+SOC vs. SOC
[STOMP, ORIOLE, ARTO, SABR-COMET, EXTEND]

n = 472 (248 MDT+SOC, 224 SOC,)
median follow-up = 41 mo
- CSPC (58%)
- treated with ADT (74%) +/- ARPI (54%)
- treated primary prostate (82%).

✅PFS 0.45 (0.35-0.58), P<0.0001
✅rPFS 0.59 (0.46-0.76), P<0.0001
✅CRFS 0.58 (0.37-0.91), P=0.020
✅OS 0.64 (0.40-1.01), P=0.057

PFS benefit across subgroups [castration, prior tx, staging, ADT/ARPI] (all HR < 0.52, all P < 0.05)

🩺Clinical implications:
- WOLVERINE demonstrated significant benefit of MDT for rPFS & CRFS (trend OS)
- Several ongoing studies to evaluate the role of MDT 👇

👥@sandysrimd @BrandonMahal @AlexSherryMD @piet_ost @drdavidpalma @EllenKimMD @MutlaySayan @DrPaulNguyen @DrRanaMcKay @Silke_Gillessen @Uromigos @DrChoueiri @neerajaiims @OncBrothers @OncoAlert @ASCO @ASCOPost @PGrivasMDPhD @AtishChoudhury @PrafulRavi1 @xiaoweimd

[Piet Ost @piet_ost]

📢 STORM trial breaking results at #ESTRO25!

🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa.

🧬 ENRT+MDT:
✅ Superior bRFS (57% vs 41%, p=0.014)
✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006)
✅ Superior MFS (76% vs 63%, p=0.06)
❌ No increase in ≥G2 GU/GI toxicity

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

https://t.co/H8pUs5hvI6

[Dr. Nina Niu Sanford @NiuSanford]

SOFT study: 141 elderly (70+), chemo-ineligible pts w locally advanced rectal cancer.

Short-course RT → delayed surgery achieved 94% R0 resection &amp; 5% local recurrence.

A v reasonable, low-burden strategy for older pts w competing risks. @OncoAlert

https://t.co/ZD1MYC6j5E

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

My 2025 ASTRO GU #radonc spring refresher presentation (+ hidden slides) is available online
https://t.co/64zwmGDBTx
#Refresher25

Rated 5/5 ⭐️⭐️⭐️⭐️⭐️
Send your feedback via QR code or https://t.co/xzQBUxMfXm

[Science News @SciencNews]

The importance of stupidity in scientific research

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

What is the ideal duration of hormone therapy for the treatment of prostate cancer?

https://t.co/E2LEjOAc0U

Video summary of https://t.co/9omNEdNL9v